Cargando…

Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations

INTRODUCTION: Dacomitinib and gefitinib are irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) indicated for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) and EGFR-activating mutations. Pharmacokinetic (PK) studies in healthy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jerry, Nickens, Dana, Wilner, Keith, Tan, Weiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593125/ https://www.ncbi.nlm.nih.gov/pubmed/34120312 http://dx.doi.org/10.1007/s40487-021-00156-2

Ejemplares similares

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
por: Mok, Tony S., et al.
Publicado: (2020)

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib
por: Ruiz-Garcia, Ana, et al.
Publicado: (2020)

Tumor growth inhibition modeling to support the starting dose for dacomitinib
por: Fostvedt, Luke K., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
por: Zhang, Longfeng, et al.
Publicado: (2021)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
por: Morita, Ayako, et al.
Publicado: (2021)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China
por: Xu, Xinglu, et al.
Publicado: (2021)

Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2020)

Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
por: Lee, Chia-Han, et al.
Publicado: (2022)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations
por: Li, Hong‐Shuai, et al.
Publicado: (2022)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
por: Pu, Xingxiang, et al.
Publicado: (2023)

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2021)

Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study
por: Li, Hong-Shuai, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2022)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
por: Li, Yibin, et al.
Publicado: (2022)

A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report
por: Zhou, Tao, et al.
Publicado: (2022)

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2015)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
por: Nio, Yuta, et al.
Publicado: (2022)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China
por: Yu, Yong-feng, et al.
Publicado: (2021)

Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer
por: Mizusaki, Shun, et al.
Publicado: (2020)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

High efficacy of gefitinib in the treatment of EGFR mutation-positive advanced non-small cell lung adenocarcinoma: A case report
por: WANG, ZHONGCHAO, et al.
Publicado: (2014)

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations
por: Jiang, Xuhong, et al.
Publicado: (2020)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
por: SUTANDYO, Noorwati, et al.
Publicado: (2019)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis
por: Zeng, Xiaohui, et al.
Publicado: (2014)

The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib
por: Yang, Li-Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o5rmln4442vi87i555calts6un